<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01930604</url>
  </required_header>
  <id_info>
    <org_study_id>BTXHH11</org_study_id>
    <nct_id>NCT01930604</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin Treatment in Craniofacial, Inguinal, Palmar, Plantar and Truncal Hyperhidrosis</brief_title>
  <official_title>Botulinum Toxin Treatment in Craniofacial, Inguinal, Palmar, Plantar and Truncal Hyperhidrosis, a Randomized, Double Blind, Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carl Swartling</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hidrosis Clinic, Stockholm, Sweden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hyperhidrosis is defined as excessive sweating and affects about 2.8 % of the population.

      It has been shown to have a deleterious effect on the quality of life measured using the
      Dermatology Life Quality Index (DLQI) which is one of the most widely used
      dermatology-specific quality of life instruments. This is comparable to the effect on quality
      of life in patients with severe psoriasis of the skin as well as to nodulocystic acne
      patients before treatment with oral isotretinoin.

      The clinical effect of Botulinum Toxin (Btx) A has been established in three randomized
      controlled trials (RCT) in axillary hyperhidrosis. One RCT has indicated a positive effect in
      palmar hyperhidrosis. Although there is increasing evidence that Btx A and B have a similar
      effect on hyperhidrosis of other parts of the body (ie hyperhidrosis of the face, trunk,
      groin and feet) which is reported in case-reports and open studies there is still a great
      need for more controlled studies. This is why we will carry out this randomized,
      double-blind, placebo-controlled study to investigate the clinical effect and safety of Btx A
      in palmar, plantar and inguinal (groins/buttocks) hyperhidrosis and the clinical effect and
      safety of Btx B in craniofacial and truncal hyperhidrosis, respectively. Besides using the
      DLQI instrument we will also study Btx A/B to elucidate the impact of this treatment on
      quality of life using a generic instrument, the effect on anxiety and depressive symptoms,
      sweating, and patients´global assessment of therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DLQI (Dermatology Life Quality Index)</measure>
    <time_frame>3±1 weeks after treatment</time_frame>
    <description>The primary endpoint is scores on DLQI-values at follow-up in the Btx A/B treatment groups when compared to the placebo groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AE (Adverse Events)</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Safety by recording of reported adverse events (AE) by the patient at the clinic visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gravimetry</measure>
    <time_frame>Before treatment and 3±1 weeks after treatment</time_frame>
    <description>The amount of sweat is measured gravimetrically.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDSS (Hyperhidrosis Disease Severity Scale)</measure>
    <time_frame>Before treatment and 3±1 weeks after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health outcome (EQ-5D)</measure>
    <time_frame>Before treatment and 3±1 weeks after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LSAS-SR (Liebowitz Social Anxiety Scale-Self Report)</measure>
    <time_frame>Before treatment and 3±1 weeks after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MADRS-S (Montgomery-Asberg Depression Rating Scale-Self report)</measure>
    <time_frame>Before treatment and 3±1 weeks after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Assessment of Therapy</measure>
    <time_frame>3±1 weeks after treatment</time_frame>
    <description>The patient will be asked at the follow-up visit (3±1 weeks after treatment) to give his/her subjective opinion and rate the effect of the treatment using a scale ranging from 1-5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DLQI (Dermatology Life Quality Index)</measure>
    <time_frame>Before treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">588</enrollment>
  <condition>Hyperhidrosis</condition>
  <arm_group>
    <arm_group_label>Palmar hyperhidrosis, Botox (onabotulinumtoxinA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Solution for injection, individual dosing, maximum dose 400 units, single treatment session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Palmar hyperhidrosis, NaCl</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plantar hyperhidrosis, Botox (onabotulinumtoxinA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Solution for injection, individual dosing, maximum dose 400 units, single treatment session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plantar hyperhidrosis, NaCl</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inguinal (groins/buttocks) hyperhidrosis, Botox (ona...)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Solution for injection, individual dosing, maximum dose 400 units, single treatment session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inguinal (groins/buttocks) hyperhidrosis, NaCl</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Craniofacial hyperhidrosis, NeuroBloc/Myobloc (rima...)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Solution for injection, individual dosing, maximum dose 2500 units, single treatment session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Craniofacial hyperhidrosis, NaCl</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Truncal hyperhidrosis, NeuroBloc/Myobloc (rimabotulinumtoxinB)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Solution for injection, individual dosing, maximum dose 5000 units, single treatment session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Truncal hyperhidrosis, NaCl</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botox (onabotulinumtoxinA)</intervention_name>
    <arm_group_label>Palmar hyperhidrosis, Botox (onabotulinumtoxinA)</arm_group_label>
    <arm_group_label>Plantar hyperhidrosis, Botox (onabotulinumtoxinA)</arm_group_label>
    <arm_group_label>Inguinal (groins/buttocks) hyperhidrosis, Botox (ona...)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NeuroBloc/Myobloc (rimabotulinumtoxinB)</intervention_name>
    <arm_group_label>Craniofacial hyperhidrosis, NeuroBloc/Myobloc (rima...)</arm_group_label>
    <arm_group_label>Truncal hyperhidrosis, NeuroBloc/Myobloc (rimabotulinumtoxinB)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl (placebo)</intervention_name>
    <arm_group_label>Palmar hyperhidrosis, NaCl</arm_group_label>
    <arm_group_label>Plantar hyperhidrosis, NaCl</arm_group_label>
    <arm_group_label>Inguinal (groins/buttocks) hyperhidrosis, NaCl</arm_group_label>
    <arm_group_label>Craniofacial hyperhidrosis, NaCl</arm_group_label>
    <arm_group_label>Truncal hyperhidrosis, NaCl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent received from patient

          -  Informed consent received from patient´s parents (when patient &lt; 18 years)

          -  Hyperhidrosis of the head, trunk, groins/buttocks, hands or feet

          -  Age &gt; 16 years

          -  Patients must be previously untreated with Btx A/B

          -  If female, patient is post-menopausal, surgically sterilized, or willing to use an
             acceptable method of birth control (i.e. a hormonal contraceptive, intra-uterine
             device, diaphragm with spermicide, condom*) throughout the study. If male with a
             female partner of childbearing potential, willing to use an acceptable method of birth
             control for the study duration of the study, for both female and male, acceptable
             birth control must be used for at least 3 months after the last dose of study
             medication.

             * A condom alone is not considered an acceptable method for birth control. Two barrier
             methods only are not considered an acceptable method of birth control.

          -  Patients must have DLQI-score ≥ 10 and HDSS-score ≥ 3

        Exclusion Criteria:

          -  Contraindication to Btx

          -  Use of aminoglycosides, tetracyclines , spectinomycin, lincomycin, polymyxin or muscle
             relaxants

          -  Pregnancy or lactation

          -  Patients unwilling to meet the requirements of the protocol

          -  Other medical or social reasons for exclusion at the discretion of the Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carl Swartling, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hidrosis Clinic, Warfvinges väg 35, Stockholm, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carl Swartling, MD, PhD</last_name>
    <phone>0046768534850</phone>
    <email>carl.swartling@svettmottagningen.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Carl Swartling</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-11251</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carl Swartling, MD, PhD</last_name>
      <phone>0046768534850</phone>
      <email>carl.swartling@svettmottagningen.se</email>
    </contact>
    <investigator>
      <last_name>Carl Swartling, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2013</study_first_submitted>
  <study_first_submitted_qc>August 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2013</study_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hidrosis Clinic, Stockholm, Sweden</investigator_affiliation>
    <investigator_full_name>Carl Swartling</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Palmar hyperhidrosis.</keyword>
  <keyword>Plantar hyperhidrosis.</keyword>
  <keyword>Inguinal (groins and buttocks) hyperhidrosis.</keyword>
  <keyword>Craniofacial hyperhidrosis.</keyword>
  <keyword>Truncal hyperhidrosis.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperhidrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>rimabotulinumtoxinB</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

